caa a22 4500 445377283 CHVBK 20180317143006.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s00702-011-0580-2 doi (NATIONALLICENCE)springer-10.1007/s00702-011-0580-2 High prevalence of malignant melanoma in Israeli patients with Parkinson's disease [Elektronische Daten] [R. Inzelberg, J. Rabey, E. Melamed, R. Djaldetti, A. Reches, S. Badarny, S. Hassin-Baer, O. Cohen, H. Trau, J. Aharon-Peretz, R. Milo, M. Schwartz, M. Huberman, L. Gilead, M. Barchana, I. Liphshiz, C. Fitzer-Attas, N. Giladi] The risk of melanoma is higher in patients with Parkinson's disease (PD) than in the general population. Whether the association is disease related or treatment related is unclear. The objective of this study was to assess melanoma prevalence in PD patients in Israel using active dermatologic screening. Consecutive patients with idiopathic PD were recruited by 12 Israeli centers. A movement disorder specialist assessed the severity of PD and obtained a medical, neurological, and medication history. Subsequently, a dermatologist assessed melanoma risk factors, recorded a dermatologic history, proactively performed a whole-body skin examination, and biopsied suspicious skin lesions. Of the enrolled patients (n=1,395, mean age 69.5±10.6years, mean PD duration 7.3±6.0years), 95.3% were treated with dopaminergic agents. Biopsies revealed 8 patients with melanoma in situ and 1 with invasive malignant melanoma; 14 patients reported a melanoma prior to enrollment. The observed 5-year limited duration prevalence of melanoma in PD patients was 4.4 times greater (95% CI 2.6-7.6) than expected from melanoma prevalence in an age- and sex-matched cohort from the Israel National Cancer Registry. The increase was accounted for by an elevated prevalence of melanoma in situ [relative risk 12.5 (95% CI 6.7-23.2)]. Occurrence of melanoma did not correlate with levodopa therapy or time of onset of PD. Melanoma prevalence in PD patients was higher than expected in the general Israeli population. This was not related to levodopa treatment. PD patients should be actively screened for melanoma on a routine basis. Springer-Verlag, 2011 Parkinson's disease/Parkinsonism nationallicence Melanoma nationallicence Prevalence nationallicence Cancer nationallicence Epidemiology nationallicence Inzelberg R. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut Rabey J. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut Melamed E. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut Djaldetti R. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut Reches A. Department of Neurology, Hadassah Hospital, Hebrew University, Jerusalem, Israel aut Badarny S. Department of Neurology, Carmel Medical Center, Haifa, Israel aut Hassin-Baer S. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut Cohen O. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut Trau H. Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel aut Aharon-Peretz J. Rappaport Faculty of Medicine, Technion, Haifa, Israel aut Milo R. Department of Neurology, Barzilai Medical Center, Ashkelon, Israel aut Schwartz M. Rappaport Faculty of Medicine, Technion, Haifa, Israel aut Huberman M. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut Gilead L. Department of Dermatology, Hadassah Hospital, Hebrew University, Jerusalem, Israel aut Barchana M. Israel Cancer Registry, Israel Ministry of Health, Jerusalem, Israel aut Liphshiz I. School of Public Health, Haifa University, Haifa, Israel aut Fitzer-Attas C. Teva Pharmaceutical Industries, Inc, Petah Tikva, Israel aut Giladi N. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut Journal of Neural Transmission Springer Vienna 118/8(2011-08-01), 1199-1207 0300-9564 118:8<1199 2011 118 702 https://doi.org/10.1007/s00702-011-0580-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00702-011-0580-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Inzelberg R. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut NATIONALLICENCE 700 1- Rabey J. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut NATIONALLICENCE 700 1- Melamed E. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut NATIONALLICENCE 700 1- Djaldetti R. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut NATIONALLICENCE 700 1- Reches A. Department of Neurology, Hadassah Hospital, Hebrew University, Jerusalem, Israel aut NATIONALLICENCE 700 1- Badarny S. Department of Neurology, Carmel Medical Center, Haifa, Israel aut NATIONALLICENCE 700 1- Hassin-Baer S. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut NATIONALLICENCE 700 1- Cohen O. The Sagol Neuroscience Center, Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel aut NATIONALLICENCE 700 1- Trau H. Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel aut NATIONALLICENCE 700 1- Aharon-Peretz J. Rappaport Faculty of Medicine, Technion, Haifa, Israel aut NATIONALLICENCE 700 1- Milo R. Department of Neurology, Barzilai Medical Center, Ashkelon, Israel aut NATIONALLICENCE 700 1- Schwartz M. Rappaport Faculty of Medicine, Technion, Haifa, Israel aut NATIONALLICENCE 700 1- Huberman M. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut NATIONALLICENCE 700 1- Gilead L. Department of Dermatology, Hadassah Hospital, Hebrew University, Jerusalem, Israel aut NATIONALLICENCE 700 1- Barchana M. Israel Cancer Registry, Israel Ministry of Health, Jerusalem, Israel aut NATIONALLICENCE 700 1- Liphshiz I. School of Public Health, Haifa University, Haifa, Israel aut NATIONALLICENCE 700 1- Fitzer-Attas C. Teva Pharmaceutical Industries, Inc, Petah Tikva, Israel aut NATIONALLICENCE 700 1- Giladi N. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel aut NATIONALLICENCE 773 0- Journal of Neural Transmission Springer Vienna 118/8(2011-08-01), 1199-1207 0300-9564 118:8<1199 2011 118 702 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer